Skip to main
GMAB
GMAB logo

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Genmab's strong performance is highlighted by the worldwide net sales of its leading product, DARZALEX, which reached $3.08 billion in Q4 2024, demonstrating its robust growth trajectory and solid positioning in the multiple myeloma market. The company benefits from a diverse pipeline of candidates and recent positive clinical trial results, such as those for RYBREVANT, which showcased statistically significant progression-free survival benefits, further enhancing market confidence. With a proven track record of profitability and a strong balance sheet, Genmab is well-equipped to navigate challenges in the biotech sector while capitalizing on upcoming clinical data catalysts.

Bears say

Genmab faces significant risks that could negatively impact its financial outlook, particularly surrounding slowing sales of its leading product, Darzalex, as well as potential failures to obtain vital label extensions and negative trial outcomes. Additionally, the company may struggle with market penetration for other therapeutics like Arzerra in relapsing multiple sclerosis and Epcoritamab, which could hinder revenue growth. Furthermore, broader macroeconomic factors, including currency fluctuations and potential long-term dilution risks, contribute to the uncertain financial environment for Genmab.

GMAB has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 10 analysts, GMAB has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.